ReviewMetabolic brain disease2025
Paeoniflorin and depression: a comprehensive review of underlying molecular mechanisms.
Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glutathione attenuates sepsis-associated encephalopathy via dual modulation of NF-κB and PKA/CREB pathways.Open medicine (Warsaw, Poland) · 2025Article
- Neuroprotection of paeoniflorin as antidepressant candidate.BioMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is one of the common mental disorders that often leads to persistent low mood, feelings of sadness or a sense of hopelessness, disinterest, or lack of pleasure in most day-to-day things. Depression is a leading cause of disability worldwide and a major contributor to the global burden of disease. Depression is a multifactorial disorder involving several interlinked pathways. A decrease in BDNF impairs neuroplasticity and synaptic function. Overactivation of the HPA axis elevates cortisol and disrupts mood regulation. Whereas/TLR-4/NF-κB activation triggers neuroinflammation, while NLRP3 inflammasome activation induces pyroptosis, promoting neuronal damage. Besides this, oxidative stress from ROS/antioxidant imbalance leads to neuronal damage and exacerbates neuroinflammatory responses. Moreover, reduced biogenic amines (like serotonin and dopamine) weaken mood regulation, and increased glutamatergic transmission leads to excitotoxicity. Together, these alterations contribute to the onset and progression of depression, necessitating a multifaceted approach. Paeoniflorin is a monoterpene glycoside isolated from the aqueous extract of the dry root of Paeonia species such as Paeonia lactiflora, Paeonia suffruticosa, and Paeonia veitchii. It exhibits a wide range of pharmacological activities, including antidepressant. anti-inflammatory, antioxidant, anticonvulsive, analgesic and hepatoprotective activities. Various reports have delineated that paeoniflorin exerts antidepressant effects by modulating the crucial mediators implicated in the pathophysiology of depression, including BDNF, CREB, NF-κB, TLR-4, NLRP3, HPA axis, ROS, serotonin, glutamate, mTOR, HMGB1, caspases, and SNARE proteins, among others, thereby providing a multitargeted defense against depression. Considering the potential of paeoniflorin in modulating these mediators, the current review is structured to explore the mechanistic interplay among these pathways in mediating its antidepressant effects.
Indexed as
Identifiers
40682677What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.